Contineum Therapeutics, Inc. Class A Common Stock Cash Flow-to-Debt Ratio
Contineum Therapeutics, Inc. Class A Common Stock cash flow-to-debt ratio. Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a Cash Flow-to-Debt Ratio of -1.07x as of June 2026, meaning its operating cash flow of $-11.50 Million could theoretically repay -1% of its total liabilities ($10.71 Million) in one year. Check Contineum Therapeutics, Inc. Class A Com cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Contineum Therapeutics, Inc. Class A Common Stock (2021–2025)
Cash flow-to-debt ratio of Contineum Therapeutics, Inc. Class A Common Stock from 2021 to 2025. Historical debt coverage capacity for Contineum Therapeutics, Inc. Class A Common Stock across 5 annual periods. Check CTNM capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Contineum Therapeutics, Inc. Class A Common Stock Cash Flow-to-Debt Ratio by Year (2021–2025)
Contineum Therapeutics, Inc. Class A Common Stock cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for Contineum Therapeutics, Inc. Class A Common Stock. For the full cash flow conversion analysis, see Contineum Therapeutics, Inc. Class A Com cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.53x | $-55.31 Million | $15.65 Million | ▼ -59.0% |
| 2024 | -2.22x | $-32.84 Million | $14.78 Million | ▼ -2377.6% |
| 2023 | 0.10x | $19.35 Million | $198.32 Million | ▲ +105.5% |
| 2022 | -1.77x | $-20.12 Million | $11.37 Million | ▲ +39.8% |
| 2021 | -2.94x | $-26.27 Million | $8.93 Million | — |